Compare Amphastar Pharmaceuticals Inc (AMPH) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Simon Property Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Simon Property Group Inc trades at $219.28 (market cap $71.52B). The key difference: Simon Property Group Inc is far larger — about 82.8× Amphastar Pharmaceuticals Inc's market cap, and Simon Property Group Inc pays a 3.99% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SPG | |
|---|---|---|
Market Cap | $863.95M | $71.52B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $236.70 |
52-Week Low | $16.87 | $169.22 |
Enterprise Value | $1.26B | $100.00B |
Dividend Yield | — | 3.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Simon Property Group (SPG) trades at $222.91, up 0.49% on the day, near its consensus price target of $223.50. The stock shows strong fundamentals with a P/E of 15.5 and robust profitability, including a net income margin of 70.59% and ROE of 127.05%. Recent Q2 2026 earnings beat expectations with FFO of $3.29 per share, driven by leasing momentum and raised guidance. Technical indicators are bearish overall, with support at $221 and resistance at $224. The company maintains a solid dividend, paying $2.25 in H1 2026.
Outlook: SPG benefits from strong operational performance and raised 2026 guidance, supported by tenant demand and property NOI growth. Investment opportunities include consistent earnings beats and a high ROE. Risks involve elevated long-term debt of $24.21 billion, potential interest rate pressures, and e-commerce competition. Analyst sentiment is mixed with 40.54% buy ratings, but technical bearish signals suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
